Literature DB >> 16009163

Effects of the ovulatory serum concentration of human chorionic gonadotropin on the incidence of ovarian hyperstimulation syndrome and success rates for in vitro fertilization.

Bruce S Shapiro1, Said T Daneshmand, Forest C Garner, Martha Aguirre, Richard Ross, Suzanne Morris.   

Abstract

OBJECTIVE: To determine whether the serum concentration of hCG on the day after hCG administration (abbreviated throughout this article as [hCG]) is related to the incidence of ovarian hyperstimulation syndrome (OHSS), oocyte recovery per follicle, fertilization, blastulation, embryo transfer, implantation, and clinical pregnancy.
DESIGN: Retrospective study.
SETTING: Private infertility clinic. PATIENT(S): The OHSS study group included 849 non-donor IVF cycles performed between January 1998 and August 2003. The study group for hCG efficacy included 248 nondonor IVF cycles performed between January 2001 and May 2003 with patients younger than 35 years of age. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Occurrence of OHSS, severity of OHSS, [hCG], proportion of follicles yielding oocytes, fertilization rate, blastulation rate, transfer rate, implantation rate, and clinical pregnancy rate. RESULT(S): No significant relationships were observed between [hCG] and the proportion of follicles yielding oocytes, fertilization rate, blastulation rate, or the probabilities of embryo transfer, implantation, or clinical pregnancy. The incidence of OHSS (all types) and OHSS requiring transvaginal paracentesis were predicted by [hCG] (P=.02 and P=.05, respectively) and with follicle count (P<.0001 in both cases). CONCLUSION(S): These results suggest that moderated hCG dosage is useful in preventing OHSS without reducing efficacy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16009163     DOI: 10.1016/j.fertnstert.2004.12.053

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  6 in total

Review 1.  Novel Concepts for Inducing Final Oocyte Maturation in In Vitro Fertilization Treatment.

Authors:  Ali Abbara; Sophie A Clarke; Waljit S Dhillo
Journal:  Endocr Rev       Date:  2018-10-01       Impact factor: 19.871

2.  Human chorionic gonadotropin serum levels following ovulation triggering and IVF cycle outcome.

Authors:  Yossi Mizrachi; Eran Horowitz; Jacob Farhi; David Levran; Arieh Raziel; Ariel Weissman
Journal:  J Assist Reprod Genet       Date:  2018-03-23       Impact factor: 3.412

3.  A unique human chorionic gonadotropin antagonist suppresses ovarian hyperstimulation syndrome in rats.

Authors:  Pratibhasri A Vardhana; Martin A Julius; Susan V Pollak; Evan G Lustbader; Rhonda K Trousdale; Joyce W Lustbader
Journal:  Endocrinology       Date:  2009-05-14       Impact factor: 4.736

4.  Ovulation triggering with GnRH agonist vs. hCG in the same egg donor population undergoing donor oocyte cycles with GnRH antagonist: a prospective randomized cross-over trial.

Authors:  A Sismanoglu; H I Tekin; H F Erden; N H Ciray; U Ulug; M Bahceci
Journal:  J Assist Reprod Genet       Date:  2009-07-23       Impact factor: 3.412

5.  Reducing the trigger dose of recombinant hCG in high-responder patients attending an assisted reproductive technology program: an observational study.

Authors:  Gian Mario Tiboni; Enrica Concetta Colangelo; Adalisa Ponzano
Journal:  Drug Des Devel Ther       Date:  2016-05-18       Impact factor: 4.162

6.  Spontaneous ovarian hyperstimulation syndrome following a thawed embryo transfer cycle.

Authors:  Mi Kyoung Kim; Hyung Jae Won; Sung Han Shim; Dong Hyun Cha; Tae Ki Yoon
Journal:  Clin Exp Reprod Med       Date:  2014-09-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.